Life sciences real estate in Europe has attracted significant interest from leading global investment managers. Our analysis combines the IPE Real Assets Top 150 ranking of investment managers with our proprietary database of life sciences real estate deals in Europe. Together, these sources reveal how the sector has evolved, highlighting 40 active managers who collectively oversee over €2.4 trillion in assets under management (AUM) across all real estate sectors.
These managers employ diverse strategies, ranging from stabilised assets to developments, with portfolios encompassing R&D labs, warehouses, point-of-care properties, and production facilities. Investment strategies include portfolio acquisitions, single-asset investments, developments, equity and debt financing, and partnerships. This report dives into the key players, notable deals, preferred markets, and emerging trends shaping this evolving landscape.
Key players in life sciences real estate
Life sciences real estate is dominated by a mix of investment managers (global and otherwise) and each bringing their own approach to the sector. These firms represent a broad spectrum of investment styles and approaches, from opportunistic strategies to long-term core investments. Below is a detailed breakdown (including total assets under management) of the top 40 managers active in this sector:
